Insider · CIK 0001643756

Aunins John G.

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001643756

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-01-29	MCRBSeres Therapeutics, Inc. · STOCK OPTION (RIGHT TO BUY)A Award	Chief Technology Officer & EVP	AAward	+300K sh	—	—	300,000
2020-01-26	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+12.5K sh	—	—	105,250
2020-01-26	MCRBSeres Therapeutics, Inc. · RESTRICTED STOCK UNITSM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−12.5K sh	—	—	0
2019-01-26	MCRBSeres Therapeutics, Inc. · RESTRICTED STOCK UNITSM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−7,500 sh	—	—	12,500
2019-01-26	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+7,500 sh	—	—	92,750
2019-01-25	MCRBSeres Therapeutics, Inc. · STOCK OPTION (RIGHT TO BUY)A Award	Chief Technology Officer & EVP	AAward	+60K sh	—	—	60,000
2018-12-19	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+10K sh	—	—	85,250
2018-12-19	MCRBSeres Therapeutics, Inc. · RESTRICTED STOCK UNITSM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−10K sh	—	—	0
2018-12-17	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$6.39	−$91.3K	75,250
2018-11-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$8.26	−$118K	89,532
2018-10-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$5.94	−$84.8K	103,811
2018-09-17	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$7.27	−$104K	118,090
2018-08-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$7.57	−$108K	132,369
2018-07-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$8.10	−$116K	160,927
2018-06-19	MCRBSeres Therapeutics, Inc. · RESTRICTED STOCK UNITSM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−5,000 sh	—	—	10,000
2018-06-19	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+5,000 sh	—	—	175,206
2018-06-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$8.57	−$122K	170,206
2018-05-15	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$8.08	−$115K	146,648
2018-04-25	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−14.3K sh	$7.58	−$108K	184,485
2018-01-30	MCRBSeres Therapeutics, Inc. · STOCK OPTION (RIGHT TO BUY)A Award	Chief Technology Officer & EVP	AAward	−40K sh	—	—	40,000
2018-01-26	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−1,738 sh	$11.02	−$19.2K	198,764
2018-01-26	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+5,000 sh	—	—	200,502
2018-01-26	MCRBSeres Therapeutics, Inc. · RESTRICTED STOCK UNITSM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−5,000 sh	—	—	20,000
2017-12-19	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+5,000 sh	—	—	61,060
2017-12-19	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−1,623 sh	$10.14	−$16.5K	195,502
2017-12-19	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+5,000 sh	—	—	197,125
2017-12-19	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−5,000 sh	—	—	15,000
2017-12-19	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−1,623 sh	$10.14	−$16.5K	59,437
2017-06-19	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Technology Officer & EVP	AAward	+20K sh	—	—	20,000
2017-01-26	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Technology Officer & EVP	AAward	+25K sh	—	—	25,000
2017-01-26	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Technology Officer & EVP	AAward	+50K sh	—	—	50,000
2016-09-19	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Technology Officer & EVP	AAward	+30K sh	—	—	30,000
2016-08-29	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−9,390 sh	$10.87	−$102K	192,125
2016-07-27	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−9,250 sh	$35.00	−$324K	201,515
2016-07-25	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−9,390 sh	$34.18	−$321K	210,765
2016-07-22	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	+188K sh	$0.48	+$90K	220,155
2016-07-22	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Technology Officer & EVP	MExercise/Conversion	−188K sh	—	—	12,500
2016-06-27	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−9,390 sh	$27.23	−$256K	32,655
2016-05-31	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−13.4K sh	$30.02	−$401K	42,695
2016-05-31	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−650 sh	$30.57	−$19.9K	42,045
2016-04-25	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−18.6K sh	$31.94	−$595K	56,060
2016-04-25	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−18.6K sh	$31.94	−$595K	56,060
2016-03-28	MCRBSeres Therapeutics, Inc.S Sale	Chief Technology Officer & EVP	SSale	−9,390 sh	$23.89	−$224K	74,700
2016-02-01	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Technology Officer & EVP	AAward	+69K sh	—	—	69,000
2015-06-26	MCRBSeres Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Chief Technology Officer & EVP	CConversion	−34.1K sh	—	—	0
2015-06-26	MCRBSeres Therapeutics, Inc.C Conversion	Chief Technology Officer & EVP	CConversion	+34.1K sh	—	—	84,090
2015-06-25	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Technology Officer & EVP	AAward	+50K sh	—	—	50,000

Recent filings

Accepted (ET)
Jan 314
Aunins John G.0000899243-20-002418
SEC(opens sec.gov)
Jan 284
Aunins John G.0000899243-20-002210
SEC(opens sec.gov)
Jan 294
Aunins John G.0000899243-19-002137
SEC(opens sec.gov)
Dec 194
Aunins John G.0000899243-18-031411
SEC(opens sec.gov)
Nov 194
Aunins John G.0000899243-18-029310
SEC(opens sec.gov)
Oct 164
Aunins John G.0000899243-18-026790
SEC(opens sec.gov)
Sep 194
Aunins John G.0000899243-18-024819
SEC(opens sec.gov)
Jul 184
Aunins John G.0000899243-18-020074
SEC(opens sec.gov)
Jun 194
Aunins John G.0000899243-18-017198
SEC(opens sec.gov)
Jun 184
Aunins John G.0000899243-18-017017
SEC(opens sec.gov)
Apr 264
Aunins John G.0000899243-18-010837
SEC(opens sec.gov)
Jan 304/A
Aunins John G.0000899243-18-002323
SEC(opens sec.gov)

Companies

Seres Therapeutics, Inc.Chief Technology Officer & EVPMCRB

Address

C/O SERES THERAPEUTICS, INC. 215 FIRST STREET

CAMBRIDGE, MA, 02142